by Brook White | Aug 26, 2020 | Blog
As the COVID-19 pandemic halted many in-person clinical trial visits, sponsors were faced with difficult decisions about whether to delay, cancel, or modify their on-going clinical trials. One option for some trials was to replace in-person visits with remote or... by Brook White | Aug 13, 2020 | Blog
As the COVID-19 pandemic made in-person visits difficult or impossible, sponsors and CROs turned to remote visits and remote assessments to keep trials running. This is an approach to which several regulators have signaled interest and VeraSci has endorsed. After... by Brook White | Jul 28, 2020 | Publications and Articles
Pharma Advances recently published “Expert opinion on Real-World Evidence (RWE) in drug development and usage” co-authored by Dr. Luca Pani, VP Regulatory Strategy and Market Access Innovation at VeraSci. This article presents the Italian Society of Pharmacology’s... by Brook White | Jul 21, 2020 | Blog
We recently wrote about the first two special meetings of the Innovative Technologies Working Group of the International Society for CNS Clinical Trials and Methodology (ISCTM) to discuss challenges related to implementing remote assessments in CNS clinical trials in... by Brook White | Jun 25, 2020 | Blog
Placebo response is a potentially devastating component of CNS trials, particularly those with subjective patient-reported outcomes and high levels of interaction with clinical staff. In pain, depression, and other psychiatric studies using subjective primary...